Introducing ioGlutamatergic Neurons HTT 50CAG/WT™ | A next-generation approach to study Huntington's disease
In this video, you will learn about the development of the human iPSC-derived glutamatergic neurons with a 50 CAG repeat expansion, the power of opti-ox powered disease models and the benefit of using genetically matched controls in the study of Huntington’s disease.
The bit.bio team offers insights into the industry-leading consistency and scalability of ioGlutamatergic Neurons HTT 50CAG/WT and the potential impact the disease model has on Huntington's disease research and drug discovery.
Find out more about the characterisation of our Huntington’s disease model in the brochure here.
Dr Tony Oosterveen | Senior Scientist
Dr Zoe Nilsson | Global Product Marketing Manager
Ben Newman | Scientist